| 1. |
Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes[J]. Br J Haematol, 2010, 149(2): 167-180. DOI: 10.1111/j.1365-2141.2010.08077.x.
|
| 2. |
Leite LFB, Máximo TA, Mosca T, et al. CD40 ligand deficiency[J]. Allergol Immunopathol (Madr), 2020, 48(4): 409-413. DOI: 10.1016/j.aller.2019.08.005.
|
| 3. |
Akarsu A, Halaçlı S, Tan Ç, et al. A single-center study points to diverse features and outcome in patients with hyperimmunoglobulin M syndrome and class- switch recombination defects[J/OL]. Scand J Immunol, 2022, 96 (5): e13213[2022-09-01]. https://pubmed.ncbi.nlm.nih.gov/36808635/. DOI: 10.1111/sji.13213.
|
| 4. |
de la Morena MT. Clinical phenotypes of hyper-IgM syndromes[J]. J Allergy Clin Immunol Pract, 2016, 4(6): 1023-1036. DOI: 10.1016/j.jaip.2016.09.013.
|
| 5. |
Yazdani R, Fekrvand S, Shahkarami S, et al. The hyper IgM syndromes: epidemiology, pathogenesis, clinical manifestations, diagnosis and management[J]. Clin Immunol, 2019, 198: 19-30. DOI: 10.1016/j.clim.2018.11.007.
|
| 6. |
França TT, Barreiros LA, Salgado RC, et al. CD40 ligand deficiency in latin America: clinical, immunological, and genetic characteristics[J]. J Clin Immunol, 2022, 42(3): 514-526. DOI: 10.1007/s10875-021-01182-5.
|
| 7. |
Banday AZ, Nisar R. Clinical and immunological features, genetic variants, and outcomes of patients with CD40 deficiency[J]. J Clin Immunol, 2023, 44(1): 17. DOI: 10.1007/s10875-023-01633-1.
|
| 8. |
Quartier P, Bustamante J, Sanal O, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency[J]. Clin Immunol, 2004, 110(1): 22-29. DOI: 10.1016/j.clim.2003.10.007.
|
| 9. |
Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome[J]. J Clin Immunol, 2008, 28(Suppl 1): S62-66. DOI: 10.1007/s10875-008-9171-x.
|
| 10. |
Bahillo P, Cantero T, Solís P, et al. Hyper-IgM syndrome with CHARGE association[J]. Pediatr Allergy Immunol, 2003, 14(6): 487-489. DOI: 10.1046/j.0905-6157.2003.00104.x.
|
| 11. |
Noordzij JG, Wulffraat NM, Haraldsson A, et al. Ataxia-telangiectasia patients presenting with hyper-IgM syndrome[J]. Arch Dis Child, 2009, 94(6): 448-449. DOI: 10.1136/adc.2008.149351.
|
| 12. |
Aghamohammadi A, Imai K, Moazzami K, et al. Ataxia-telangiectasia in a patient presenting with hyper-immunoglobulin M syndrome[J]. J Investig Allergol Clin Immunol, 2010, 20(5): 442-445.
|
| 13. |
Schuster A, Apfelstedt-Sylla E, Pusch C, et al. Autoimmune retinopathy with RPE hypersensitivity and 'negative ERG' in X-linked hyper-IgM syndrome[J]. Ocul Immunol Inflamm, 2005, 13(2-3): 235-243. DOI: 10.1080/09273940590928571.
|
| 14. |
Grange L, Dalal M, Nussenblatt RB, et al. Autoimmune retinopathy[J]. Am J Ophthalmol, 2014, 157(2): 266-272. DOI: 10.1016/j.ajo.2013.09.019.
|
| 15. |
Fox AR, Gordon LK, Heckenlively JR, et al. Consensus on the diagnosis and management of nonparaneoplastic autoimmune retinopathy using a modified delphi approach[J]. Am J Ophthalmol, 2016, 168: 183-190. DOI: 10.1016/j.ajo.2016.05.013.
|
| 16. |
Hubbard N, Hagin D, Sommer K, et al. Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome[J]. Blood, 2016, 127(21): 2513-2522. DOI: 10.1182/blood-2015-11-683235.
|
1/5
